ResearcherSana Kliniken AGActive in the last 2 years

Markus Dommach

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5048203265. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 9

Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Werner Hartwig · 1 shared paper, 2026 · strength 0.32
- Paper Case Report: Long-term remission of metastatic pancreatic ductal adenocarcinoma after surgery and high-dose nicotinamid… DOI 10.3389/fonc.2026.1927317 ↗
Hubert Kolb · 1 shared paper, 2026 · strength 0.32
- Paper Case Report: Long-term remission of metastatic pancreatic ductal adenocarcinoma after surgery and high-dose nicotinamid… DOI 10.3389/fonc.2026.1927317 ↗
Beate S. Schultheis · 1 shared paper, 2017 · strength 0.05
- Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343 ↗
Wolfgang Ekkehard Schmidt · 1 shared paper, 2017 · strength 0.05
- Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343 ↗
Ralf‐Dieter Hofheinz · 1 shared paper, 2017 · strength 0.05
- Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343 ↗
Sara De Dosso · 1 shared paper, 2017 · strength 0.05
- Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343 ↗
Jens Thomas Siveke · 1 shared paper, 2017 · strength 0.05
- Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343 ↗
Dirk Strumberg · 1 shared paper, 2017 · strength 0.05
- Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343 ↗
Şuayib Yalçın · 1 shared paper, 2017 · strength 0.05
- Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.